Cytophage Technologies Ltd.
Developer of engineered bacteriophage solutions for food safety, animal health, and human therapeutics. Operates a phage design platform and strain libraries to generate natural and genetically modified bacteriophages, conducts on-farm and pilot studies to evaluate efficacy, pursues regulatory approvals for food-safety and clinical applications, and collaborates with clinical partners to support individual-patient phage therapy.
Industries
Nr. of Employees
small (1-50)
Cytophage Technologies Ltd.
Products
Poultry bacteriophage product for broiler health
Phage-based treatment developed for broiler chickens to reduce pathogenic bacteria, lower mortality, and improve sellable meat yield as an alternative to prophylactic antibiotics.
Egg-shell surface bacteriophage treatment
Surface-applied phage formulation designed to reduce Salmonella and other Enterobacteriaceae contamination on egg shells in production and hatchery environments.
Food-processing surface bacteriophage treatment
Surface-applied phage product validated to reduce target pathogens on raw poultry and meat-processing surfaces to support food-safety workflows.
Lyophilized oral phage tablets for poultry gut health
Lyophilized tablet formulation for oral delivery aimed at improving poultry gut health and reducing intestinal bacterial disease.
Swine bacteriophage cocktail for herd health
Multi-phage cocktail targeting common swine pathogens intended as an alternative to antibiotics for disease prevention in swine production.
Bovine mastitis phage product
Phage-based product concept targeted at bacterial mastitis in cattle intended to reduce bacterial burden and support udder health.
Poultry bacteriophage product for broiler health
Phage-based treatment developed for broiler chickens to reduce pathogenic bacteria, lower mortality, and improve sellable meat yield as an alternative to prophylactic antibiotics.
Egg-shell surface bacteriophage treatment
Surface-applied phage formulation designed to reduce Salmonella and other Enterobacteriaceae contamination on egg shells in production and hatchery environments.
Food-processing surface bacteriophage treatment
Surface-applied phage product validated to reduce target pathogens on raw poultry and meat-processing surfaces to support food-safety workflows.
Lyophilized oral phage tablets for poultry gut health
Lyophilized tablet formulation for oral delivery aimed at improving poultry gut health and reducing intestinal bacterial disease.
Swine bacteriophage cocktail for herd health
Multi-phage cocktail targeting common swine pathogens intended as an alternative to antibiotics for disease prevention in swine production.
Bovine mastitis phage product
Phage-based product concept targeted at bacterial mastitis in cattle intended to reduce bacterial burden and support udder health.
Services
Design and produce tailored phage combinations targeting specified bacterial pathogens for food, animal or clinical applications.
Design and run pilot and on-farm trials in commercial production and processing environments to evaluate efficacy and production outcomes.
Advisory services and preparation of regulatory materials to support market notifications, letters of no objection, and other regulatory pathways for phage-based products.
Collaboration with hospital partners and physicians to identify candidates, secure ethics approvals, and provide phage material for compassionate or investigational individual-patient treatments.
Design and produce tailored phage combinations targeting specified bacterial pathogens for food, animal or clinical applications.
Design and run pilot and on-farm trials in commercial production and processing environments to evaluate efficacy and production outcomes.
Advisory services and preparation of regulatory materials to support market notifications, letters of no objection, and other regulatory pathways for phage-based products.
Collaboration with hospital partners and physicians to identify candidates, secure ethics approvals, and provide phage material for compassionate or investigational individual-patient treatments.
Expertise Areas
- Bacteriophage engineering and therapeutic development
- Animal-health product development (poultry, swine, cattle)
- Food-safety interventions and surface decontamination
- Clinical phage therapy support and case-by-case investigational use
Key Technologies
- Bacteriophage engineering and synthetic phage design
- Phage genetic modification and host-range engineering
- Phage display for antigen presentation
- Lyophilization and oral tablet formulation
News & Updates
Follow-up EU pilot study reported decreased mortality and improved sellable meat yield for a poultry bacteriophage product, supporting its use as an alternative to prophylactic antibiotics in broiler production.
Health Canada issued Letters of No Objection for two phage-based food-safety products following review of safety and efficacy data, enabling regulated market access pathways in Canada.
Announcement of two patient candidates for an investigational phage product targeting Staphylococcus aureus in prosthetic joint infections, with ethics and regulatory approvals in process.
Announcement of a distribution agreement with a national agricultural distributor to enable commercial availability of an egg-surface phage product across Canada.
Company announced a non-brokered private placement as part of fundraising activities.
Company announced closing date for previously announced non-brokered unit private placement.
Follow-up EU pilot study reported decreased mortality and improved sellable meat yield for a poultry bacteriophage product, supporting its use as an alternative to prophylactic antibiotics in broiler production.
Health Canada issued Letters of No Objection for two phage-based food-safety products following review of safety and efficacy data, enabling regulated market access pathways in Canada.
Announcement of two patient candidates for an investigational phage product targeting Staphylococcus aureus in prosthetic joint infections, with ethics and regulatory approvals in process.
Announcement of a distribution agreement with a national agricultural distributor to enable commercial availability of an egg-surface phage product across Canada.
Company announced a non-brokered private placement as part of fundraising activities.
Company announced closing date for previously announced non-brokered unit private placement.